# Cross-session log — guideline-risk-intelligence Wave 2 report — 2026-08-31

PROJECT_ID: `pitavastatin-ezetimibe-evidence` · RUN_ID: `2026-08-31-v1`
Logged by: Research Director (`pit-eze-research-director`)

## IN — guideline-risk-intelligence Wave 2 report (condensed; full text in transcript)

`BLOCKED_FOR_SOURCE` (items 1-2/4), `READY_WITH_PENDING_ITEMS` overall. All three assigned priority
PDFs (2026 ACC/AHA, Taiwan STS 2026, ESC 2025 Focused Update) blocked by HTTP 403 Cloudflare
bot-challenge via both `curl` and `WebFetch`, corroborated by Europe PMC metadata
(`is_open_access:False`, no PMCID for any). No workaround attempted — correctly identified as
detection-evasion territory, out of scope. Gate-2 LlamaParse demonstration satisfied instead on a
substitute open-access source (T-014, Razavi/Blumenthal 2026 editorial, PMCID PMC13326120) — full
provenance recorded, but this source does not discuss ezetimibe, so the combination-therapy-wording
task item is unfulfilled. **Caught and discarded a tool-confabulation incident**: a `WebFetch` call
on the ESC 2025 landing page fabricated specific quantitative content and a locator while also
correctly reporting the page as paywalled — discarded entirely, never recorded. Found T-015
(REPRIEVE trial) in T-014's reference list, routed to trials-efficacy rather than claimed. Asked:
(1) can the PI supply any of the 3 blocked PDFs directly, (2) route REPRIEVE, (3) confirm next
priority.

→ Decision 2026-08-31-13 (BLOCKED_FOR_SOURCE, 3 documents), 2026-08-31-14 (confabulation incident,
new `CLAUDE.md` §9 caution), 2026-08-31-15 (T-015/REPRIEVE logged, routed) all added.
`02_SOURCE-INVENTORY.md` updated: T-005, T-007, #28 marked BLOCKED_FOR_SOURCE (full text); T-014,
T-015 added as new rows.

## OUT — Director replies

To guideline-risk: commended all three findings (correct bot-detection stop, confabulation catch,
correct routing discipline on REPRIEVE), confirmed T-014 as an acceptable Gate-2 substitute with
its caveat noted, escalated the "can PI supply blocked PDFs" question to the PI directly (see the
report delivered to the user this turn), confirmed item 6 (numeric-threshold work on
already-accessible documents) as the next priority.
To trials-efficacy: routed T-015 (REPRIEVE) for independent verification, with the
monotherapy/HIV-population distinction flagged so it isn't conflated with HIJ-PROPER or RACING.

## Status

trials-efficacy and safety-pharmacology have not yet reported their Wave 2 results as of this entry.
One PI-facing question outstanding (blocked-PDF supply) — see `04_OPEN-QUESTIONS.md`.
